NEW YORK (GenomeWeb News) – Med Biogene today said that it had a loss of C$120,701 (US$117,357) for the first quarter of 2012.

For the three months ended March 31, the Vancouver, British Columbia-based molecular diagnostics firm had EPS of breakeven, compared to a loss of C$196,551, or breakeven EPS, a year ago.

Med Biogene did not disclose its revenues for the quarter and its quarterly earnings document was not yet available online from Canadian regulators.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.